Epirubicin in colorectal cancer

Holdener, Eduard E.; Hansen, Heine H.; Höst, H. F.; Bruntsch, U; Cavalli, Franco; Rénard, Josette; Pinedo, Herbert H.M.; Rozencweig, Marcel

doi:10.1007/bf00176826

Cited by 19 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Five phase I1 studies with single agent epirubicin have been published (206)(207)(208)(209)(210). The dose of epirubicin was increased from 75 to 150mg/m2 every 3 weeks.…”

Section: Colorectal Cancermentioning

confidence: 99%

Current Status of Epirubicin (Farmorubicin) in the Treatment of Solid Tumours

et al. 1990

View full text Add to dashboard Cite

“…Five phase I1 studies with single agent epirubicin have been published (206)(207)(208)(209)(210). The dose of epirubicin was increased from 75 to 150mg/m2 every 3 weeks.…”

Section: Colorectal Cancermentioning

confidence: 99%

Current Status of Epirubicin (Farmorubicin) in the Treatment of Solid Tumours

et al. 1990

View full text Add to dashboard Cite

“…Epirubicin is a doxorubicin derivative anthracycline analog that has a better therapeutic index than doxorubicin [14]. With the same dose, epirubicin elicits lower hematologic and cardiac toxicity than doxorubicin [15].…”

Section: Introductionmentioning

confidence: 99%

GRP78 Knockdown Enhances Apoptosis via the Down-Regulation of Oxidative Stress and Akt Pathway after Epirubicin Treatment in Colon Cancer DLD-1 Cells

Chang

Huang

et al. 2012

PLoS ONE

View full text Add to dashboard Cite

IntroductionThe 78-kDa glucose-regulated protein (GRP78) is induced in the cancer microenvironment and can be considered as a novel predictor of responsiveness to chemotherapy in many cancers. In this study, we found that intracellular reactive oxygen species (ROS) and nuclear factor erythroid 2-related factor 2 (Nrf2) nuclear translocation were higher in GRP78 knockdown DLD-1 colon cancer cells compared with scrambled control cells.Methodology/Principal FindingsTreatment with epirubicin in GRP78 knockdown DLD-1 cells enhanced apoptosis and was associated with decreased production of intracellular ROS. In addition, apoptosis was increased by the antioxidants propyl gallate (PG) and dithiothreitol (DTT) in epirubicin-treated scrambled control cells. Epirubicin-treated GRP78 knockdown cells resulted in more inactivated Akt pathway members, such as phosphorylated Akt and GSK-3β, as well as downstream targets of β-catenin expression. Knockdown of Nrf2 with small interfering RNA (siRNA) increased apoptosis in epirubicin-treated GRP78 knockdown cells, which suggested that Nrf2 may be a primary defense mechanism in GRP78 knockdown cells. We also demonstrated that epirubicin-treated GRP78 knockdown cells could decrease survival pathway signaling through the redox activation of protein phosphatase 2A (PP2A), which is a serine/threonine phosphatase that negatively regulates the Akt pathway.ConclusionsOur results indicate that epirubicin decreased the intracellular ROS in GRP78 knockdown cells, which decreased survival signaling through both the Akt pathway and the activation of PP2A. Together, these mechanisms contributed to the enhanced level of epirubicin-induced apoptosis that was observed in the GRP78 knockdown cells.

show abstract

“…The search for a better anthracycline has only produced a few clinically useful analogs, as shown above in Figure 1.1. These include the semi-synthetic DOX analog epirubicin (EPI) and the DNR analog idarubicin (IDA) (Holdener, 1985;Lopez, 1984;Daghestani, 1985;Ganzina, 1986).…”

Section: Anthracycline Structural Features and Semi-synthetic Analogsmentioning

confidence: 99%

Potent and Potentially Non-Cardiotoxic Anthracyclines: Their Synthesis, Biological Evaluation, and Comparison of Hydrozone-Mediated Reductions

Holdaway¹

View full text Add to dashboard Cite

show abstract

Epirubicin in colorectal cancer

Cited by 19 publications

References 5 publications

Current Status of Epirubicin (Farmorubicin) in the Treatment of Solid Tumours

Current Status of Epirubicin (Farmorubicin) in the Treatment of Solid Tumours

GRP78 Knockdown Enhances Apoptosis via the Down-Regulation of Oxidative Stress and Akt Pathway after Epirubicin Treatment in Colon Cancer DLD-1 Cells

Potent and Potentially Non-Cardiotoxic Anthracyclines: Their Synthesis, Biological Evaluation, and Comparison of Hydrozone-Mediated Reductions

Contact Info

Product

Resources

About